---
schema_version: "secwatch.filing_event.v1"
accession: "0001831283-23-000129"
form_type: "8-K"
ticker: "LIANY"
cik: "0001831283"
company_name: "LianBio"
filed_at: "2023-12-01T23:59:59+00:00"
generated_at: "2026-06-07T19:32:03.267686+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# LianBio confirms unsolicited $4.30/share buyout proposal from Concentra plus CVR

## Summary
- Proposal: $4.30 per share cash plus a contingent value right for 80% of net proceeds from licensing or disposition of LianBio's programs.
- Concentra Biosciences (controlled by Tang Capital Partners) made the offer; Tang Capital currently holds ~8.6% of LianBio.
- Proposal requires LianBio to have at least $515 million in cash and cash equivalents at closing, net of liabilities and costs.
- Board is reviewing the unsolicited non-binding proposal in the best interests of shareholders; further announcement expected.

## SEC filing metadata
- accession: 0001831283-23-000129
- form_type: 8-K
- ticker: LIANY
- cik: 0001831283
- company_name: LianBio
- filed_at: 2023-12-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831283/000183128323000129/0001831283-23-000129-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831283/000183128323000129/lian-20231130.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001831283-23-000129
- JSON: https://secwatch.observer/filing/0001831283-23-000129.json
- Plain text: https://secwatch.observer/filing/0001831283-23-000129.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.